Merck & Co., Inc. (NYSE:MRK) sixth Annual Evercore ISI HealthCONx Convention Transcript November 30, 2023 1:20 PM ET


Dr. Eliav Barr – Senior Vice President, Head, International Medical Improvement and CMO

Peter Dannenbaum – Vice President, Investor Relations


Umer Raffat – Evercore

Umer Raffat

Thanks. Hear, thanks guys for being right here. Apologies. I’m a pair minutes behind. Pleasure to have Merck administration be a part of us. That is our final hearth of this convention, not less than on my finish.

Dr. Eliav Barr


Query-and-Reply Session

Q – Umer Raffat

So actually wanting ahead to it. Peter promised it’ll be motion packed. And so let’s bounce proper into it. I believe it’ll be an ideal thought. Possibly let me flip it over to you, Peter, and to kick issues off, perhaps body for us what’s on prime by way of precedence listing in your thoughts and we’ll bounce proper in.

Peter Dannenbaum

Certain. This has been an incredible yr for Merck and we’re wanting ahead to 2024. The issues which might be prime of thoughts for us is sustained information on KEYTRUDA, particularly in early-stage cancers. The — you’re going to see numerous Part III begins for all of our antibody drug conjugates that we have now partnered with Kelun and with Daiichi Sankyo. A lot of efforts in precision drugs and oncology, in addition to, in fact, V116, the submitting after which hopefully, if all goes properly, the approval of that.

Sotatercept is ought to be industrial — coming into the industrial house and we’re wanting ahead to seeing that. There could also be further information coming from the continued research which might be occasion pushed, just like the ZENITH research. And as we’ve talked about earlier than, our PCS — oral PCSK9, MK-0616 has began Part III packages, together with our cardiovascular end result trial.


Source link